Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07419074

Enrollment

Registered

2026-02-18

Start date

2025-09-01

Completion date

2026-01-01

Last updated

2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipid Profile

Keywords

Garcinia cambogia, Garcinia gummi-gutta, hypoglycemic effect, pre-diabetic, obesity, hydroxycitric acid (HCA), glucose metabolism

Brief summary

Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited. Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.

Detailed description

The observed effects are likely mediated by HCA, which inhibits ATP-citrate lyase, reducing de novo lipogenesis, enhancing glucose utilization, and modulating adipokines and oxidative stress. Conclusion: Garcinia cambogia rind powder supplementation exerts dose-dependent metabolic benefits in pre-diabetic obese adults, improving anthropometric, glycemic, lipid, hepatic, and renal parameters without adverse effects. It may serve as a complementary intervention alongside lifestyle modification for the management of obesity and pre-diabetes.

Interventions

DIETARY_SUPPLEMENTGarcinia cambogia rind powder

Once a day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Participants of both genders were included if they were aged 30-60 years, * body mass index (BMI) ≥30 kg/m², * Individuals with HbA1c levels ranging from 5.7% to 10% were selected, .indicating pre-diabetic to diabetic status. Participants were required to have a .body mass index (BMI) of 25 kg/m² or higher

Exclusion criteria

* Participants who were diagnosed with type 1, pregnant or lactating, * chronic liver, kidney, or cardiovascular disease, * history of hepatotoxicity or gastrointestinal disorders, * using weight-loss supplements, steroids, or lipid-lowering drugs, or had a known allergy to Garcinia cambogia

Design outcomes

Primary

Measure	Time frame
Weight	12 weeks

Secondary

Measure	Time frame
Lipid profile	12 weeks
fasting glucose	12 weeks

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026